Annual Report 2024

Annual Report 2024

2025 Outlook

The information below is subject to risks and uncertainties that may materially impact the achievement of our 2025 outlook. For more information, please refer to section ”Risk Factors” of this Annual Report for a discussion of such risks and uncertainties.

VYVGART

Saudi Arabia gMG IV decision on approval expected

1H 2025
More about VYVGART

VYVGART SC

US PFS decision on approval expected for gMG and CIDP

1H 2025

Health Canada PFS decision on approval expected for gMG and CIDP

2H 2025

EMA CIDP decision on approval expected

1H 2025
More about VYVGART SC

efgartigimod

CIDP Phase 4 switch clinical trial topline results expected

2H 2025

ADAPT-SERON Phase 3 clinical trial topline results expected

2H 2025

LN Phase 2 topline results expected

2H 2025
More about efgartigimod

empasiprubart

CIDP Phase 3 expected to initiate

1H 2025

DGF Phase 2 interim analysis

2H 2025
More about empasiprubart

ARGX-119

CMS Phase lb topline results expected

2H 2025

SMA Phase 2 expected to initiate

2H 2025
More about ARGX-119

4 INDs

ARGX-109 Phase 1 expected to initiate

1H 2025

ARGX-109 Phase 1 topline data expected

2H 2025

ARGX-213 Phase 1 expected to initiate

1H 2025

ARGX-121 Phase 1 expected to initiate

1H 2025

ARGX-220 Phase 1 expected to initiate

2H 2025
More about INDs